ABSTRACT Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin D 2 , has been reported to have a close connection with cardiovascular disease and sleep regulation. This study aimed to test the hypothesis that the L-PGDS level is a useful marker to identify patients with obstructive sleep apnoea.
Introduction
L-PGDS was confirmed to be secreted into blood and urine [14] , and we have established a system to measure its urine, serum or plasma levels by an ELISA system [14, [17] [18] [19] . L-PGDS is a very stable enzyme and is highly resistant to heat treatment [14] and protease digestion [20] , whereas PGD 2 is an unstable substance, as mentioned earlier [13] . L-PGDS is localised where PGD 2 would have its effect, that is, in the central nervous system, male genital organs and the human heart. In the human heart, L-PGDS is localised in myocardial and atrial endocardial cells, smooth muscle cells in the arteriosclerotic intima, and in the atherosclerotic plaques of severely stenotic coronary arteries. In addition, the chemical properties of L-PGDS are similar to those of serum albumin; however, its molecular weight is much smaller than that of serum albumin (26 000 versus 66 000 Da). Thus, L-PGDS more easily passes through glomerular capillary walls of the kidney than serum albumin. Indeed, it has been reported that urinary L-PGDS excretion increased in the microalbuminuric stage in patients with type 2 diabetes mellitus (DM) and in hypertensive patients who were apparently free from overt proteinuria [21, 22] . Although the enzymatic activity of L-PGDS cannot be determined, the amount of serum or urinary L-PGDS increased when conditions such as coronary heart disease, hypertension or type 2 DM worsened [21] [22] [23] .
As OSA induces multi-organ damage and diseases such as hypertension, DM, renal insufficiency, coronary disease and cerebral-cardiovascular diseases, the degree of severity of OSA in individuals with OSA would have significant associations with morbidity and mortality from these conditions [24] . In addition, serum L-PGDS levels were slightly elevated in individuals with OSA with excessive daytime sleepiness [25] . Thus, we hypothesised that L-PGDS could be a biomarker for OSA because of its close relationships with sleep and CVD. In consideration of this hypothesis, we tested whether plasma or urine L-PGDS would be a powerful biomarker for OSA.
Methods
Study subjects 64 clinically stable adults (age .20 years) with suspected OSA were consecutively enrolled in the present prospective study. This study is registered at www.clinicaltrials.gov with identifier number NCT01096433.
Major exclusion criteria were history of CVD, DM under treatment with hypoglycaemic agents or insulin, use of glucocorticoid or nonsteroidal anti-inflammatory drugs, and being a current smoker. This study was approved by the Ethics Committee of Kyoto University (Kyoto, Japan). All patients gave written informed consent to participate. The other exclusion criteria are shown, in detail, in the online supplementary material.
Study design
At baseline, the subjects' medical history was recorded and a physical examination was performed. In the medical history, hypertension was defined as a systolic blood pressure o140 mmHg or diastolic blood pressure o90 mmHg, or use of an antihypertensive medication. Dyslipidaemia was defined as serum lowdensity lipoprotein cholesterol o140 mg?dL -1 or high-density lipoprotein cholesterol (HDL-C) ,40 mg?dL -1 , triglycerides o150 mg?dL -1 [26] , or use of an antilipidaemic medication.
All patients underwent attended diagnostic overnight PSG. Before the patient slept, urine samples were collected at 22:00 h. In addition, the first urine voided in the morning following the overnight PSG was collected at 06:00 h. Peripheral venous blood samples were collected from 06:00 h to 7:00 h following a 12-h overnight fast and PSG. Morning endothelial dysfunction measured by reactive hyperaemia peripheral arterial tone (RH-PAT) [27] was measured. After the overnight PSG, five blood pressure measurements, each 1 min apart, were taken in the morning after the patient had rested for at least 5 min in the supine position. The average of the latter two readings was calculated.
After 2 days of continuous positive airway pressure (CPAP) treatment, urine and blood samples were collected at the same time as during and after PSG. In all of the patients, adequate CPAP pressure was determined to have overcome obstruction and all flow limitations by a full night's titration.
During the PSG day, we investigated the circadian variations in urinary L-PGDS concentrations in 25 patients who were randomly selected from all 64 subjects at 4-h intervals except for midnight (14:00, 18:00, 22:00, 06:00 and 10:00 h). Urinary sampling was not performed at midnight in order not to disturb physiological sleep. 
Polysomnography

Measurements of plasma and urinary L-PGDS concentrations
In the present study, plasma samples were centrifuged immediately at 14706g at 4uC for 15 min and urine samples were pooled (not centrifuged), as described previously [15, [17] [18] [19] . The separated samples were stored at -80uC until assay. Concentrations of urinary or plasma L-PGDS were measured by an ELISA using two monoclonal antibodies, Mab-7F5 and Mab-1B7, as described previously (online supplementary material) [15, [17] [18] [19] .
With this ELISA system, it has been demonstrated that intra-and interassay coefficients of variation in urine samples ranged from 3.2% to 5.8% and 7.6% to 8.3%, respectively. The intra-and interassay coefficients of variation in serum samples were 3.6% and 5.8%, respectively. The ELISA showed no significant interference by a variety of urinary constituents [18] . In addition, it was shown that serum and plasma L-PGDS values in individual subjects were almost the same [15] . All the samples were measured in duplicate and the results were averaged.
Other parameters
Venous blood samples were taken in the fasting state in the morning after one night of PSG and examined for markers of glucose and lipid metabolism and C-reactive protein.
As it was difficult to measure urinary catecholamine and L-PGDS levels at the same time, we measured plasma catecholamine levels.
Measurements of the RH-PAT
The RH-PAT is a newly established method to measure endothelial function [27] . Endothelial dysfunction as measured by RH-PAT has been reported in patients with OSA [28] . Morning endothelial function assessed by a finger plethysmographic device (Itamar Medical Ltd., Caesarea, Israel) that allows the isolated detection of pulsatile arterial volume changes [27] was measured after an overnight PSG and after 2 days of CPAP.
Statistical analysis
Data were analysed using JMP 9.0 (SAS Institute, Inc., Cary, NC, USA). Continuous variables were expressed as mean¡SE or median values and ranges because the sample size of each group was small. The associations between patients' characteristics, PSG data, biomarkers (blood and urine) and OSA severity were assessed by the Kruskal-Wallis test. When a significant difference was observed, we used the Bonferroni-corrected t-test to identify where differences were significant. We evaluated the sensitivity and specificity of the cut-off value of L-PGDS for predicting severe OSA with the use of receiver operating characteristic curve analysis, estimating the area under the curve (AUC). The relationship between L-PGDS concentrations (urine and plasma), the RH-PAT index and other parameters were analysed by Pearson's correlation coefficient test. Multiple regression analysis was performed to adjust for confounders such as age, sex, body mass index (BMI), and morning systolic and diastolic blood pressure. Next, multiple regression analyses, with a p-value ,0.10 required for entry into the models, were performed to identify those variables that could best predict morning urinary L-PGDS.
To investigate changes in L-PGDS concentrations, the RH-PAT index, and other parameters before and after 2 days of CPAP, comparisons of data between those two time-points were tested by a paired t-test. Multiple ANOVA with repeated measures was performed to analyse urinary L-PGDS concentrations across the 24-h period. In all analyses, p-value ,0.05 was considered statistically significant.
Results
Clinical characteristics of study subjects, L-PGDS concentration and RH-PAT index according to OSA severity Patient characteristics, PSG data and laboratory data are shown in table 1. There were significant differences among the groups in morning urinary L-PGDS concentrations (p50.0009) but not in night urinary L-PGDS concentrations (p50.19) and plasma L-PGDS levels (p50.09) (table 1 and fig. 1a ). After adjustment for age and BMI, subjects with severe OSA had significantly higher morning urinary L-PGDS values than control subjects (p50.007) and subjects with moderate OSA (p50.002). There were significant differences among the groups in the RH-PAT index ( fig. 1b ).
The cut-off value for predicting severe OSA with minimal false-negative and false-positive errors was 621.8 ng?mg -1 of creatinine (sensitivity 65.2%, specificity, 85.4%). This cut-off value had moderate accuracy for predicting severe OSA (AUC 0.78) ( fig. 2 ).
Relationship between urinary L-PGDS concentrations, RH-PAT index and clinical indices
Morning urinary L-PGDS concentrations were positively correlated with several parameters, including the AHI (table 2 and fig. 3 ). Morning urinary L-PGDS concentrations were positively correlated with AHI after adjustment for age, sex, BMI and morning systolic and diastolic blood pressure ( fig. 3 ). There was a strongly positive correlation between morning and night urinary L-PGDS concentrations (p,0.0001). The Epworth Sleepiness Scale did not correlate significantly with morning urinary L-PGDS (table 2).
After adjustment for age, sex, BMI, and morning systolic and diastolic blood pressure, morning urinary L-PGDS concentrations were still positively correlated with the AHI (b coefficient50.373; p50.006), 3% oxygen desaturation index (ODI) (b50.322; p50.02), arousal index (b50.370; p50.007) and plasma noradrenaline (b50.258; p50.04). The RH-PAT index was negatively correlated with the AHI (b5 -0.305; p50.04) and arousal index (b5 -0.359; p50.01) after adjustment.
Relationship between plasma L-PGDS concentrations and clinical indices
Plasma L-PGDS levels were positively correlated with several parameters (table 2) . Plasma L-PGDS also tended to have a positive correlation with morning urinary L-PGDS (p50.07). After adjustment for age, sex, BMI, and morning systolic and diastolic blood pressure, plasma L-PGDS levels were only positively correlated with serum creatinine levels (b50.361; p50.03). Table 3 shows results of multiple regression analyses to identify those variables (morning systolic and diastolic blood pressure, arousal index, AHI, 3% ODI, serum HDL-C, plasma adrenalin, plasma noradrenalin and plasma L-PGDS) that could predict morning urinary L-PGDS concentrations. Then, one of the variables that had very strong co-linearity (r.0.70), such as the arousal index, AHI and 3% ODI, was selected.
Clinical determinants of morning urinary L-PGDS concentrations
In these three models, morning urinary L-PGDS had a significant and independent correlation with the AHI or the 3% ODI, or the arousal index and serum HDL-C (table 3) .
Effects of CPAP treatment on urinary L-PGDS concentrations
In Japan, patients whose AHI is o20 can use CPAP under the health insurance system. In this study, 20 permitted patients were investigated (table 4). 12 of the 20 patients had severe OSA. 
Circadian variations in urinary L-PGDS concentrations
Circadian variations in urinary L-PGDS concentrations are shown in figure 5a. In 25 patients, a multiple ANOVA with repeated measures revealed a significant time-dependent fluctuation (p50.0002), with the highest levels at 14:00 h and lowest levels at 06:00 h. Compared with the 06:00 h values, urinary L-PGDS concentrations significantly increased at 14:00 h (p,0.0001) and 18:00 h (p50.02). Regarding the associations between the AHI and urinary L-PGDS concentrations at each time-point, the 06:00 h values were only significantly positively correlated with AHI (r50.566; p50.004). In the patients with AHI o30, 06:00 h values for urinary L-PGDS were significantly increased compared with patients with AHI ,30 (AHI ,30 (n513) 227 ng?mg -1 of creatinine versus AHI o30 (n512) 780.3 ng?mg -1 of creatinine; p50.003) ( fig. 5b ).
Discussion
The major findings of our study are that morning urinary L-PGDS concentrations were positively correlated with the severity of OSA as indicated by AHI, 3% ODI and the arousal index after adjustment for several confounding factors, and that urinary L-PGDS was significantly elevated in patients with severe OSA in comparison with control subjects and those with moderate OSA. Multivariate modelling of L-PGDS determinants revealed that HDL-C and the AHI, 3% ODI or the arousal index were significantly and independently associated with the morning urinary L-PGDS (table 3) . However, it is of interest that urinary L-PGDS levels at 14:00 h were the same in the non-to-moderate and severe OSA patients. Our results also showed that morning urinary L-PGDS concentrations were decreased to control values after only 2 days of CPAP treatment, although the RH-PAT did not change. These results suggest that the urinary L-PGDS concentration might be a moderately useful marker to identify patients with severe OSA.
In the current study, subjects with severe OSA had elevated urinary L-PGDS values and decreased endothelial function determined by the RH-PAT index whereas the relationship between urinary L-PGDS and the RH-PAT index was not significant. Therefore, the combined measurement of endothelial function and L-PGDS may be a useful tool for finding and managing patients with severe OSA.
Prostaglandin systems, including PGD 2 , are very important in health maintenance and disease prevention, but they are either chemically or metabolically unstable. Therefore, substitutions such as L-PGDS are used as parameters for identifying the functions and effects of prostaglandin systems. Previous studies have demonstrated that L-PGDS levels in serum, cerebrospinal fluid or urine were elevated in patients with cardiovascular, neurological and renal diseases [21, 23, 29, 30] . The elevation in L-PGDS concentration occurs at an early stage of CVD, and the concentrations of serum or urinary L-PGDS were shown to increase when diseases such as coronary heart disease or type 2 DM worsen [21] [22] [23] , although the activity of L-PGDS is not well known. OSA induces multi-organ damage such as hypersomnolence and CVD. Therefore, it is supposed that L-PGDS could have significant associations with the pathophysiology and severity of OSA. In addition, a urinary biomarker is attractive because urine is easily obtained and the results of urine testing are easy to follow. Although our present data might not be definitive because of the small sample size, the information gained from this study appears to be of interest and the topic warrants further study.
It has been said that serum L-PGDS levels increase with age and are higher in males than in females [19] , while urinary L-PGDS was also shown to be higher in males than in females and is weakly correlated with age in female subjects [22] . In that study [22] , control subjects were slightly younger, but not with significance, and those in the moderate and severe OSA groups were almost the same age as those in the present study (table 1) . In addition, morning urinary L-PGDS values were still correlated with the severity of OSA after adjustment for BMI, age and sex. Therefore, BMI, sex and age could not be considered to have significant effects on our results. Although L-PGDS concentrations were shown to be increased in essential hypertension [21] , morning urinary L-PGDS values were still correlated with the severity of OSA after adjustment for blood pressure. The BMI in individuals with severe OSA was slightly but not significantly higher than in the other groups. It was reported that the BMI [21] was not associated with elevations in blood or urinary L-PGDS. In addition to the fact that morning urinary L-PGDS levels were significantly higher after adjustment for BMI, morning urinary L-PGDS concentrations were also significantly decreased after 2 days of CPAP, which is a specific treatment for OSA, although other factors remained the same. Furthermore, from the viewpoint of circadian measurements, morning urine L-PGDS levels were higher in patients with severe OSA than in the other subjects, while values at 14:00 h were the same. These findings indicate that L-PGDS is related to OSA independently, and is especially related to severe OSA.
Several causes for elevated L-PGDS concentrations in OSA have been considered, especially in severe OSA. First, intermittent hypoxia induces COX2 expression and activity, which in turn accelerate arachnoid acid metabolism to PGH 2 and PGE 2 [31, 32] . HAN et al. [33] noted that the expression levels of L-PGDS mRNA and protein in the heart of C57BL/6 mice were significantly increased after 14 days of hypoxia (10% oxygen) compared with mice kept under normoxia. OSA is characterised by repeated episodes of oxygen desaturation; however, in OSA there is also sustained hypoxaemia, which is expressed by arterial oxygen saturation measured by pulse oximetry ,90% (% of total sleep time). Thus, both sustained and intermittent hypoxaemia could possibly increase urinary L-PGDS. Secondly, hypoxia causes pulmonary vasoconstriction and increases pulmonary artery pressure [34] . It has been reported that fluid shear stress increases the expression of L-PGDS in vascular endothelial cells [35, 36] and that urinary PGD 2 metabolites were increased in primary pulmonary hypertension [37] . SEMENZA [38] reported that intermittent hypoxaemia induced systemic hypertension and that sustained hypoxaemia induced pulmonary hypertension. Both systemic and pulmonary hypertension induced by OSA might increase L-PGDS values [21, 37] .
It has been shown that sleep fragmentation and arousals caused by sleep apnoea induce an elevation of sympathetic activation [39] . If the severity of OSA might be associated with urinary or plasma L-PGDS concentrations, we thought that it would be important to determine whether there is a significant relationship between sympathetic activation and urinary or plasma L-PGDS. Therefore, we wanted to measure urinary catecholamine concentrations as indicators of sympathetic activity. However, it was difficult to obtain urine in which L-PGDS and catecholamine levels could be measured at the same time. Therefore, even though we knew that plasma catecholamine levels were unstable and easily variable, the usefulness of which was difficult to understand, we measured plasma catecholamine levels. In the present study, urinary L-PGDS concentrations were also correlated with plasma adrenaline and noradrenaline. Therefore, sympathetic overactivity in OSA [40, 41] might also induce increases in urinary L-PGDS. The relationship between urinary catecholamine and L-PGDS should be studied in the future. We also found that HDL-C was a significant determinant of morning urinary L-PGDS. MIWA et al. [42] reported that L-PGDS played a role in lipid transport. Therefore, HDL-C might be a significant factor along with the arousal index or the AHI in determining the urinary L-PGDS levels.
The present study is the first to demonstrate the circadian variations in urinary L-PGDS concentrations in OSA. Urinary L-PGDS values in both severe and non-to-moderate OSA were highest and at the same levels at 14:00 h, with the lowest values at 06:00 h in both groups. However, only 06:00 h urinary L-PGDS values correlated significantly with the AHI and were significantly higher in those with severe OSA compared with subjects with AHI ,30 events?h -1 . In the current study, we showed that morning urinary L-PGDS concentrations were positively correlated with the AHI, 3% ODI and arousal index. Through the circadian change in L-PGDS, we propose that L-PGDS might be a stress marker that increases during daytime and decreases during sleep, whereas the decrease in L-PGDS levels in OSA, especially severe OSA, during sleep is attenuated because intermittent or sustained hypoxia, sleep fragmentation and arousals caused by OSA lead to increased stress, including oxidative stress and sympathetic activation during sleep [39] . Additionally, occurrences of CVDs peak from morning to noon, while OSA patients have an increased risk of myocardial infarction between 00:00 h and 06:00 h compared with non-OSA patients [43] . These circadian rhythms mimic the pattern of urinary L-PGDS in this study ( fig. 4a ).
In the current study, we did not detect a significant relationship between plasma L-PGDS and the AHI, whereas morning urinary L-PGDS levels were significantly positively correlated with the AHI. Although the reason for this discrepancy is unclear, HIRAWA et al. [44] reported that urinary protein excretion in the early stage of DM was correlated with urinary L-PGDS excretion, but not with plasma L-PGDS levels. In addition, serum L-PGDS levels were not shown to be associated with the AHI [25] . The influence of OSA, such as intermittent hypoxaemia, might have a significant effect on the renal system, which induced the differences in values between plasma and urinary L-PGDS. The differences in L-PGDS levels between plasma and urine should be studied in animal models. Furthermore, we did not collect peripheral blood samples at 22:00 h in the current study. The night plasma L-PGDS concentrations or the differences between morning and night plasma L-PGDS may contribute to elucidating the relation between plasma L-PGDS and OSA.
This study had some limitations. First, the sample size was small. However, the differences in the urinary L-PGDS values between control, moderate and severe OSA patients were large and, therefore, the results could be considered significant and definitive. Secondly, it is unclear whether the effect of CPAP on the PGD 2 system would persist over the long term. A long-term prospective study is needed to clarify this issue. Thirdly, we could not conduct a comparison between CPAP users and sham CPAP users. A future study that makes comparisons between CPAP users and sham CPAP users is warranted. Fourthly, we used spot urine samples for measurement of L-PGDS. There is a possibility that several factors, such as reabsorption at tubules and physical activity, influenced the urinary L-PGDS concentrations. However, use of overnight spot urine for measurement of L-PGDS has been validated because of the correlation between L-PGDS values of overnight urine and urine collected over 24 h [44] . Therefore, we believe overnight spot urine sampling is sufficient to evaluate the role of L-PGDS in OSA.
In conclusion, based on our results, in addition to circadian data, urinary L-PGDS might be a moderately useful marker for severe OSA. From these preliminary data, urine L-PGDS measurement may be a simple and cost-effective method to screen for and manage severe OSA. This method should be tested in unselected samples in the future because it is often difficult, costly and time consuming to find patients with OSA, while the number of OSA patients who should be treated is large.
